MYDAYIS
Peakdextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate
NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYDAYIS is a once-daily extended-release oral capsule combining four amphetamine salts (dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate). It is indicated for attention-deficit/hyperactivity disorder (ADHD) and works by increasing dopamine and norepinephrine activity in the central nervous system. The extended-release formulation provides sustained symptom control throughout the day.
$0.003BPart D
Peak3.0 years to LOEProduct is in peak revenue phase with established market presence; brand teams are focused on market share defense and patient retention amid high competitive pressure (8/10).
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on MYDAYIS at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.